Arrowhead Pharmaceuticals (ARWR) Operating Leases (2019 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly Operating Leases came in at $107.9 million in Q1 2026, down 5.63% YoY from $114.3 million in Q1 2025, and up 5.63% on a QoQ basis from $102.1 million in Q4 2025.
Arrowhead Pharmaceuticals (ARWR) Operating Leases (2019 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 8 years of Operating Leases data on file, last reported at $107.9 million in Q1 2026.
- Quarterly Operating Leases fell 5.63% year-over-year to $107.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.9 million (down 5.63% YoY) and the FY2025 annual result came in at $104.1 million, down 6.23% from the prior year.
- Operating Leases advanced to $107.9 million in Q1 2026, from $102.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $118.1 million in Q2 2024 to a low of $22.7 million in Q1 2022.
- A 5-year average of $96.7 million and a median of $104.6 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 265.22% — and 2025, when it decreased 11.85%.
- Tracing ARWR's Operating Leases over 5 years: stood at $82.1 million in 2022, then surged by 40.21% to $115.2 million in 2023, then grew by 0.61% to $115.9 million in 2024, then decreased by 11.85% to $102.1 million in 2025, then gained by 5.63% to $107.9 million in 2026.
- The last three Operating Leases figures came in at $107.9 million (Q1 2026), $102.1 million (Q4 2025), and $104.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arrowhead Pharmaceuticals | 12.23 Bn | 10.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 119.62 Mn |
| Mar 31, 2026 | 107.88 Mn |
| Dec 31, 2025 | 102.13 Mn |
| Sep 30, 2025 | 104.11 Mn |
| Jun 30, 2025 | 112.70 Mn |
| Mar 31, 2025 | 114.31 Mn |
| Dec 31, 2024 | 115.86 Mn |
| Sep 30, 2024 | 111.03 Mn |
| Jun 30, 2024 | 118.09 Mn |
| Mar 31, 2024 | 113.63 Mn |
| Dec 31, 2023 | 115.16 Mn |
| Sep 30, 2023 | 104.61 Mn |
| Jun 30, 2023 | 79.91 Mn |
| Mar 31, 2023 | 80.07 Mn |
| Dec 31, 2022 | 82.13 Mn |
| Sep 30, 2022 | 78.80 Mn |
| Jun 30, 2022 | 81.11 Mn |
| Mar 31, 2022 | 22.70 Mn |
| Dec 31, 2021 | 22.49 Mn |
| Sep 30, 2021 | 23.30 Mn |